Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: Safety, efficacy and pharmacokinetics

Haemophilia

Volumn 19, Issue 5, 2013, Pages 698-705

  Kulkarni, R ^a   Karim, F A ^b   Glamocanin, S ^c   Janic, D ^d   Vdovin, V ^e   Ozelo, M ^f   Rageliene, L ^g   Carboni, E ^h   Laguna, P ⁱ   Dobaczewski, G ^j   Seremetis, S ^k   Lindblom, A ^l   Santagostino, E ^m  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b National Blood Centre   (Malaysia)

^c UNIVERSITY CHILDREN S HOSPITAL   (Macedonia)

^d UNIVERSITY CHILDREN S HOSPITAL   (Serbia)

^e NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g VILNIUS UNIVERSITY   (Lithuania)

^h HOSPITAL PEQUENO PRÍNCIPE   (Brazil)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

^j WROCLAW MEDICAL UNIVERSITY   (Poland)

^k NOVO NORDISK INC   (United States)

^l NOVO NORDISK A S   (Denmark)

^m FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

more..

Author keywords

Haemophilia A; Paediatric population; Pharmacokinetics; Prophylaxis; Recombinant factor VIII; Turoctocog alfa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

AREA UNDER THE CURVE; ARTICLE; BLEEDING; CHILD; CLINICAL TRIAL; DEVICE INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG OVERDOSE; DRUG SAFETY; HEMOPHILIA A; HEMOSTASIS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RHINOPHARYNGITIS; SCHOOL CHILD; SOFT TISSUE INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS;

HAEMOPHILIA A; PAEDIATRIC POPULATION; PHARMACOKINETICS; PROPHYLAXIS; RECOMBINANT FACTOR VIII; TUROCTOCOG ALFA;

CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; INFANT; MALE;

EID: 84883055547     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12165     Document Type: Article

References (17)

1. Ljung RC. Can haemophilic arthropathy be prevented? Br J Haematol 1998; 101: 215-9.
2. Thim L, Vandahl B, Karlsson J et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010; 16: 349-59.
3. Lusher JM. Development and introduction of recombinant factor VIII - a clinician's experience. Haemophilia 2012; 18: 483-6.
4. Lusher JM. Inhibitors in young boys with haemophilia. Baillieres Best Pract Res Clin Haematol 2000; 13: 457-68.
5. Lentz SR, Misgav M, Ozelo M et al. Results from a large multinational clinical trial (guardian 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severre haemophilia A: safety and efficacy. Haemophilia 2013; 19: 691-7.
6. ®)-an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011; 17: 854-9.
7. EMA. Committee for medicinal products for human use (CHMP), Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009. 2011.
8. WMA. Declaration of Helsinki - ethical principles for medical research involving human subjects. 2010.
9. ICH. Tripartite harmonised guideline: good clinical practice: consolidated guideline (E6). 2010.
10. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-5.
11. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den BM, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
12. Christiansen ML, Balling KW, Persson E et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878-87.
13. Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 2012; 120: 720-7.
14. Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
15. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
16. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695-702.
17. Bjorkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-8.